The drugmaker stopped paying 340B discounts to hospitals that didn’t comply with its new paperwork requirements late last week. Hospitals are urging HRSA to step in.
Hospitals irate after Eli Lilly follows through on 340B ultimatum Read More »
Formed by Sofinnova Partners and former Sanofi executive Frédéric Marrache, Bionyra Pharma emerged from stealth Monday with an initial focus in inflammatory bowel disease and atopic dermatitis.
Sofinnova, Sanofi alum unveil Bionyra with $165M and next-gen immunology assets Read More »
Results for Definium Therapeutics psychedelic candidate for major depressive disorder “exceeded expectations,” according to Stifel, while Jefferies called the efficacy data “profound.”
Definium’s LSD-based therapy elicits ‘profound’ efficacy in Phase 3 depression trial Read More »
The resubmission for RGX-121, expected in the third quarter, comes as the FDA has deemed REGENXBIO’s existing data “sufficient” to support an accelerated filing. It immediately follows a similar reversal of position regarding uniQure’s embattled Huntington’s disease gene therapy.
REGENXBIO to resubmit application for Hunter gene therapy after FDA’s most recent pivot Read More »
About two months into CEO Belén Garijo’s new tenure, Sanofi’s R&D chief has departed, with Xaira’s chief medical officer set to take charge of the pharma’s pipeline.
Sanofi’s R&D head exits, with AI biotech Xaira’s exec stepping in Read More »
As uniQure prepares its closely watched Huntington’s disease gene therapy for FDA review, the biotech is also making waves in chronic epilepsy with another gene therapy that Stifel says is off to a “promising start.”
UniQure’s chronic epilepsy gene therapy ‘should be on investors’ radar’ Read More »
Insilico Medicine and SK Biopharmaceuticals will use generative AI to develop novel therapies for unspecified neuroimmune disorders.
Insilico’s AI design engine bags deal with Korean biotech worth possible $2.5B+ Read More »
Eli Lilly plans to use BioArctic’s technology to shuttle an undisclosed drug candidate into the brain. The pharma hasn’t specified which neurodegenerative disease it will target.
Lilly bets up to $800M for BioArctic’s brain delivery tech Read More »
If secured, AbbVie will add Apogee’s IL-23 blocker to its current immunology stalwarts Skyrizi and Rinvoq, which have helped the pharma ride out the steep patent cliff left behind from mega-blockbuster drug Humira.
AbbVie nears $11B Apogee buy to challenge juggernaut Dupixent Read More »
Nura Bio will use the series B financing to carry two neuroprotective drug candidates through early- to mid-stage clinical studies, one targeting ALS and the other for a broader neurological profile.
Nura raises $73.8M to target ALS through a unique target Read More »
